{
    "nct_id": "NCT05900986",
    "official_title": "An Open-label, Single-arm, Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of LS301-IT in Female Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for Ductal Carcinoma in Situ (DCIS) or Stage I-II Primary Invasive Breast Cancer",
    "inclusion_criteria": "* DCIS (whether or not undergoing planned SLNB) or patients with Stage I-II, primary invasive carcinoma of the breast undergoing SLNB for which the patient's primary surgical treatment is single breast partial mastectomy.\n* ECOG performance status of 0 to 2\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 80 Years",
    "exclusion_criteria": "* Contraindications for surgery.\n* Simultaneous bilateral lumpectomies and bilateral partial mastectomies.\n* History of drug-related anaphylactic reactions, including those attributed to indocyanine green (ICG) or other agents used in the study\n* Prior chemotherapy, endocrine therapy, or biologic therapy for current clinically or biopsy proven breast cancer for Period 1.\n* Open surgery in the ipsilateral breast within a period of 1 year before administration of LS301-IT.\n* History of radiation therapy to the chest.\n* The lymphatic imaging agent ICG cannot be used prior to the partial mastectomy and SLNB procedures on the day of surgery.",
    "miscellaneous_criteria": ""
}